J Rheum Dis.  2022 Apr;29(2):59-60. 10.4078/jrd.2022.29.2.59.

Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis

• Suh CH

• KMID: 2527543
• DOI: http://doi.org/10.4078/jrd.2022.29.2.59

Reference

1. Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. 2022; The lupus nephritis management renaissance. Kidney Int. 101:242–55. DOI: 10.1016/j.kint.2021.09.012. PMID: 34619230.

2. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. 2020; Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 383:1117–28. DOI: 10.1056/NEJMoa2001180. PMID: 32937045.

3. Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. 2021; Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 397:2070–80. DOI: 10.1016/S0140-6736(21)00578-X.

4. Weidenbusch M, Römmele C, Schröttle A, Anders HJ. 2013; Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 28:106–11. DOI: 10.1093/ndt/gfs285. PMID: 22764193.

5. Cervera R, Mosca M, Ríos-Garcés R, Espinosa G, Trujillo H, Bada T, et al. 2019; Treatment for refractory lupus nephritis: rituximab vs triple target therapy. Autoimmun Rev. 18:102406. DOI: 10.1016/j.autrev.2019.102406. PMID: 31654743.

6. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2020; 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 79:713–23. DOI: 10.1136/annrheumdis-2020-216924. PMID: 32220834.

7. Teng S, Tian Y, Luo N, Zheng Q, Shao M, Li L. 2022; Efficacy and safety of an anti-CD20 monoclonal antibody, rituximab, for lupus nephritis: a meta-analysis. Int J Rheum Dis. 25:101–9. DOI: 10.1111/1756-185X.14240. PMID: 34811947.

8. Choi SJ, Ahn SM, Oh JS, Hong S, Lee CK, Yoo B, et al. 2022; Initial preserved renal function as a predictor of favorable renal response to rituximab in refractory or relapsing lupus nephritis: a single-center cohort study in Korea. J Rheum Dis. 29:22–32. DOI: 10.4078/jrd.2022.29.1.22.

9. Caster DJ, Powell DW. 2019; Utilization of biomarkers in lupus nephritis. Adv Chronic Kidney Dis. 26:351–9. DOI: 10.1053/j.ackd.2019.09.001. PMID: 31733719. PMCID: PMC7001747.

10. Radin M, Miraglia P, Barinotti A, Fenoglio R, Roccatello D, Sciascia S. 2021; Prognostic and diagnostic values of novel serum and urine biomarkers in lupus nephritis: a systematic review. Am J Nephrol. 52:559–71. DOI: 10.1159/000517852. PMID: 34515043.

11. Davies JC, Midgley A, Carlsson E, Donohue S, Bruce IN, Beresford MW, et al. 2020; Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open. 6:e001257. DOI: 10.1136/rmdopen-2020-001257. PMID: 32723832. PMCID: PMC7722276.

12. Davies JC, Carlsson E, Midgley A, Smith EMD, Bruce IN, Beresford MW, et al. 2021; A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. Rheumatology (Oxford). 60:3747–59. DOI: 10.1093/rheumatology/keaa851. PMID: 33313921. PMCID: PMC8328509.